MBRX · Moleculin Biotech, Inc.
$2.14
+0.04 (+1.90%)
At close · Jul 20
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$11.42M
Shares
5.34M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.14
Open$2.10
Day$2.06–2.16
52W$1.79–24.00
Avg vol 30d805K
Short int1.4M · 26.5% float · 1.0d
Short vol44%
Last earningsMay 14, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−57%
below
Price vs 50-day avg
−15%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−53%
trailing
YTD return
−35%
this year
Relative strength
−60%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
26.49% of float · ▲ +22.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — 13F breadth
Squeeze score
65
elevated · 0–100
Fundamentals
Free cash flow
$-22.7M
Balance sheet
$8.9M
net cash
Quant / Vol
risk profile
Volatility
110%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
10.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−57%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
26.49% of float · ▲ +22.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $2
Now $2 · 2%
52-wk high $24
vs 200-day avg -57%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MBRX
this stock
Moleculin Biotech, Inc.
|
$11.42M | -35.3% | — | — | 26.5% |
|
ONC
BeOne Medicines Ltd.
|
$448.86B | +2.2% | +22179.2% | 913.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.95B | +6.0% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.47B | -12.8% | +20.8% | 16.4 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +0.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MBRX | -3.2% | -25.7% | -53.0% | -23.3% | -35.4% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | -2.2% | -25.1% | -60.1% | -22.7% | -44.2% |